SciELO - Scientific Electronic Library Online

vol.16 número1Bloqueo interescalénico ecoguiado: ventajas en pediatríaBloqueo ciático continuo con catéter estimulador guiado mediante ecografía para tratamiento del miembro fantasma doloroso índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados




Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google


Revista de la Sociedad Española del Dolor

versão impressa ISSN 1134-8046


VALVERDE, S. et al. Utility of Vimang® formulations in patients with knee osteoarthrosis. Rev. Soc. Esp. Dolor [online]. 2009, vol.16, n.1, pp.32-41. ISSN 1134-8046.

Osteoarthrosis (OA) is the most common form of arthritis and localization in the knee is common. Symptomatic slow acting drugs for osteoarthritis include antioxidant agents as possible modifiers of disease progression. Vimang‚ is a registered brand name that covers several formulations of Mangifera indica L., used for its antioxidant, antiinfl ammatory, analgesic and immunomodulatory properties. The aim of the present study was to determine the analgesic activity of Vimang tablets and cream in patients with knee OA and identify possible posttreatment functional improvement. A further aim was to characterize the effects of Vimang on the synovial infl ammation (effusion and proliferation) associated with this entity using ultrasonography. Ten patients from Hogar Santovenia with a clinical-radiological diagnosis of knee OA were studied. Mean daily pain scores on an 11-point Likert scale were 4 or higher in the week prior to treatment initiation. The Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index was evaluated in the initial consultation and at the end of the study. Ultrasonographic examination (ALOKA device 1100 with a 7.5 mHz transducer) of the soft tissue of both knees was performed. The patients were randomly assigned to three groups. Group 1 (n = 3) received a daily dose of 1,800 mg/day (tablets), group 2 (n = 4) received 900 mg/day (tablets) and group 3 (n = 3) received a combination of tablets 900 mg/day and Vimang cream 1.2%. The tables were administered in three daily doses every 8 hours and the cream was applied three times per day every 8 hours on the affected knee. Treatment duration was 3 months. Satisfactory analgesia was achieved in all patients from days 15-21 until 3 months. This effect was at least partly related to the decrease in synovial effusion observed in most affected joints and was independent of the reduction in synovial thickness observed on ultrasound. Both effects, the increase and decrease in synovial thickness, were independent of the analgesia. The inhibition of synovial membrane proliferation compared with initial values was signifi cant only in group 2. Quality of life improved in all patients, due to pain relief and the increase in functional capacity as measured by the WOMAC index.

Palavras-chave : Osteoarthrosis; Gonarthrosis; Pain; Vimang®; Mangiferin.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )


Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons